NASDAQ:ONVO

Organovo - ONVO Stock Forecast, Price & News

$3.04

-0.23 (-7.03%)

(As of 08/15/2022 12:00 AM ET)

Add

Compare

Today's Range: $2.92
▼
$3.20
50-Day Range: $1.71
▼
$3.55
52-Week Range: $1.71
▼
$8.13

Volume: 47,291 shs
Average Volume: 66,048 shs
Market Capitalization: $26.48 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

About Organovo (NASDAQ:ONVO) Stock

Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. The company was incorporated in 2007 and is headquartered in Solana Beach, California.

Analyst Upgrades and Downgrades

Separately, StockNews.com started coverage on shares of Organovo in a research report on Tuesday, August 9th. They set a "sell" rating on the stock.

Organovo Trading Down 0.6 %

Shares of ONVO opened at $3.26 on Monday. Organovo has a 52 week low of $1.71 and a 52 week high of $8.13. The firm's 50-day simple moving average is $2.54 and its 200 day simple moving average is $2.94.

Organovo (NASDAQ:ONVO - Get Rating) last announced its quarterly earnings results on Friday, June 10th. The medical research company reported ($0.22) EPS for the quarter. The company had revenue of $1.50 million for the quarter.

Receive ONVO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Organovo and its competitors with MarketBeat's FREE daily newsletter.

ONVO Stock News Headlines

August 12, 2022 | finance.yahoo.com

Global 4D Printing Market is Predicted to Grow at a CAGR of ~40% during 2022-2031; Increasing Adoption of Novel 4D Printing in Biomedical Sciences such as Prostheses to Elevate Growth - Research Nester - Yahoo Finance

August 2, 2022 | americanbankingnews.com

Organovo (NASDAQ:ONVO) Coverage Initiated by Analysts at StockNews.com

July 28, 2022 | globenewswire.com

By 2028, Demand for Global 3D Printing in Healthcare Market Size to Surpass US$ 3120.06 Million, at a 19.02% CAGR Growth: Comprehensive Research Report by Facts & Factors - GlobeNewswire

July 26, 2022 | americanbankingnews.com

StockNews.com Begins Coverage on Organovo (NASDAQ:ONVO)

July 20, 2022 | finance.yahoo.com

The Global Human Organoids Market is expected to grow by $ 1.18 bn during 2022-2026, accelerating at a CAGR of 16.9% during the forecast period - Yahoo Finance

July 20, 2022 | uk.finance.yahoo.com

The Global Human Organoids Market is expected to grow by $ 1.18 bn during 2022-2026, accelerating at a CAGR of 16.9% during the forecast period - Yahoo Finance UK

July 19, 2022 | finance.yahoo.com

Outlook on the 3D Printing Software and Services Global Market to 2031 - Cost-Effectiveness, Greater Design Flexibility, and Low Wastage are Driving Growth - Yahoo Finance

July 19, 2022 | uk.finance.yahoo.com

Outlook on the 3D Printing Software and Services Global Market to 2031 - Cost-Effectiveness, Greater Design Flexibility, and Low Wastage are Driving Growth - Yahoo Finance UK

July 12, 2022 | nasdaq.com

Pre-market Movers: AWX, GOEV, CSSE, OB, KSPN… - Nasdaq

July 8, 2022 | seekingalpha.com

ONVO, FFIE and MYMD among pre market gainers - Seeking Alpha

July 8, 2022 | finance.yahoo.com

We're Not Very Worried About Organovo Holdings' (NASDAQ:ONVO) Cash Burn Rate

May 29, 2022 | finance.yahoo.com

4D Printing Market [2022] Size, Share, Growth | Type & Application, Trends, Key Players, Revenue and Gross Margin, Market Drivers, Opportunities, Challenges, Stakeholders and Forecast 2029 Research | Market Reports World - Yahoo Finance

May 28, 2022 | finance.yahoo.com

3D Printed Medical Devices Global Market Report 2022 - Yahoo Finance

May 20, 2022 | in.investing.com

Add Innovation To Your Portfolio With This 3D Printing ETF - Investing.com India

May 17, 2022 | globenewswire.com

Organovo Achieves 3D Tissue Model for Crohn's Disease - GlobeNewswire

May 17, 2022 | finance.yahoo.com

Organovo Achieves 3D Tissue Model for Crohn’s Disease

May 11, 2022 | investing.com

Organovo Holdings Inc (ONVO)

March 14, 2022 | benzinga.com

Human Organoids Market | Latest Innovation, Advance Technology, Top Companies Forecast 2022-2031 - Benzin - Benzinga

March 7, 2022 | finance.yahoo.com

The Global Human Liver Models Market is expected to grow by $ 1.91 bn during 2022-2026, decelerating at a CAGR of 12.94% during the forecast period - Yahoo Finance

March 5, 2022 | benzinga.com

USD 1.91 Bn growth opportunity in Human Liver Models Market | North America to account for highest growth - Benzinga

March 4, 2022 | fool.com

Why Organovo Holdings, Inc. Stock Soared 49.7% This Week - The Motley Fool

March 4, 2022 | nasdaq.com

Why Organovo Holdings, Inc. Stock Soared 49.7% This Week - Nasdaq

March 3, 2022 | finance.yahoo.com

UPDATE -- Organovo and BICO (CELLINK) Reach Licensing Agreement on Bioprinting Patents - Yahoo Finance

March 1, 2022 | globenewswire.com

UPDATE -- Organovo and BICO (CELLINK) Reach Licensing - GlobeNewswire

March 1, 2022 | finance.yahoo.com

UPDATE -- Organovo and BICO (CELLINK) Reach Licensing Agreement on Bioprinting Patents

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive ONVO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Organovo and its competitors with MarketBeat's FREE daily newsletter.

ONVO Company Calendar

Last Earnings: 6/10/2022
Today: 8/16/2022
Next Earnings (Estimated): 8/19/2022
Fiscal Year End: 3/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ONVO
CUSIP: N/A
CIK: 1497253
Web: www.organovo.com
Phone: (858) 224-1000
Fax: N/A
Employees: 12
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($1.31)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-11,450,000.00
Net Margins: N/A
Pretax Margin: -808.47%
Return on Equity: -37.71%
Return on Assets: -34.51%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 20.99
Quick Ratio: 20.99

Sales & Book Value

Annual Sales: $1.50 million
Price / Sales: 17.66
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.47 per share
Price / Book: 0.88

Miscellaneous

Outstanding Shares: 8,712,000
Free Float: 8,364,000
Market Cap: $26.48 million
Optionable: Optionable
Beta: 1.10

Key Executives

Mr. Keith E. Murphy (Age 50)
Exec. Chairman & Principal Exec. Officer
Comp: $397.18k
Dr. Jeffrey N. Miner (Age 60)
Chief Scientific Officer
Comp: $221.09k
Mr. Thomas Einar Jurgensen J.D. (Age 65)
MS, Gen. Counsel & Corp. Sec.
Comp: $264.86k
Mr. Thomas P. Hess CPA (Age 58)
MBA, Chief Financial Officer
Dr. Curtis M. Tyree Ph.D.
Sr. VP of Strategy & Bus. Devel.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ONVO Stock - Frequently Asked Questions

How have ONVO shares performed in 2022?: Organovo's stock was trading at $3.63 at the start of the year. Since then, ONVO stock has decreased by 16.3% and is now trading at $3.04.
View the best growth stocks for 2022 here.
When is Organovo's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, August 19th 2022.
View our ONVO earnings forecast.
How were Organovo's earnings last quarter?: Organovo Holdings, Inc. (NASDAQ:ONVO) announced its earnings results on Friday, June, 10th. The medical research company reported ($0.22) EPS for the quarter. The medical research company earned $1.50 million during the quarter.
When did Organovo's stock split?: Organovo shares reverse split on the morning of Wednesday, August 19th 2020. The 1-20 reverse split was announced on Monday, August 17th 2020. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, August 18th 2020. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.
What is Taylor Crouch's approval rating as Organovo's CEO?: 3 employees have rated Organovo Chief Executive Officer Taylor Crouch on Glassdoor.com. Taylor Crouch has an approval rating of 38% among the company's employees. This puts Taylor Crouch in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Organovo own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Organovo investors own include Brainstorm Cell Therapeutics (BCLI), NVIDIA (NVDA), Aerojet Rocketdyne (AJRD), Blackstone (BX), LADENBURG THALM/SH SH (LTS), Advanced Micro Devices (AMD), Exelixis (EXEL), Micron Technology (MU), Novavax (NVAX) and OPKO Health (OPK).
What is Organovo's stock symbol?: Organovo trades on the NASDAQ under the ticker symbol "ONVO."
Who are Organovo's major shareholders?: Organovo's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Nikko Asset Management Americas Inc. (5.33%), Sumitomo Mitsui Trust Holdings Inc. (5.33%), ARK Investment Management LLC (3.35%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Douglas Jay Cohen and Steven George Hughes.
View institutional ownership trends.
How do I buy shares of Organovo?: Shares of ONVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Organovo's stock price today?: One share of ONVO stock can currently be purchased for approximately $3.04.
How much money does Organovo make?: Organovo (NASDAQ:ONVO) has a market capitalization of $26.48 million and generates $1.50 million in revenue each year. The medical research company earns $-11,450,000.00 in net income (profit) each year or ($1.31) on an earnings per share basis.
How can I contact Organovo?: Organovo's mailing address is 440 STEVENS AVENUE SUITE 200, SOLANA BEACH CA, 92075. The official website for the company is www.organovo.com. The medical research company can be reached via phone at (858) 224-1000 or via email at ir@organovo.com.

This page (NASDAQ:ONVO) was last updated on 8/16/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here